Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors

CompletedOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2012

Study Completion Date

November 30, 2014

Conditions
NeurotoxicityUnspecified Adult Solid Tumor, Protocol Specific
Interventions
PROCEDURE

management of therapy complications

Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.

Trial Locations (2)

44109

MetroHealth Medical Center, Cleveland

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00305799 - Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors | Biotech Hunter | Biotech Hunter